ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING

ACTIVITY OF THE PAN-HER TYROSINE KINASE (TK) INHIBITOR DACOMITINIB (PF-00299804) IN REFRACTORY NONADENOCARCINOMA (NON-A) NON-SMALL CELL LUNG CANCER (NSCLC) AND COMPARED WITH ERLOTINIBIN THE 2ND-/3RD-LINE SETTING

Opis bibliograficzny
Główni autorzy:	Blackhall, F, Gadgeel, S, Reckamp, K, Talbot, D, Barrios, C, Krzakowski, M, Liang, J, O'Connell, J
Format:	Journal article
Wydane:	2012

Podobne zapisy

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
od: Ramalingam, S, i wsp.
Wydane: (2012)

Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
od: Justin P Williams, i wsp.
Wydane: (2014-01-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
od: Jinyao Zhang, i wsp.
Wydane: (2021-12-01)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
od: Lavacchi D, i wsp.
Wydane: (2019-09-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
od: Xingxiang Pu, i wsp.
Wydane: (2023-10-01)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
od: Qian Shen, i wsp.
Wydane: (2021-12-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
od: Ayako Morita, i wsp.
Wydane: (2021-04-01)

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
od: Jian Liu, i wsp.
Wydane: (2024-01-01)

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
od: Petros D. Grivas, i wsp.
Wydane: (2013-10-01)

Tumor growth inhibition modeling to support the starting dose for dacomitinib
od: Luke K. Fostvedt, i wsp.
Wydane: (2022-09-01)

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer
od: George D. Wilson, i wsp.
Wydane: (2021-01-01)

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer
od: Shun Mizusaki, i wsp.
Wydane: (2021-01-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
od: Ji Eun Shin, i wsp.
Wydane: (2025-02-01)

Drug-induced liver injury associated with dacomitinib: A case report
od: Xuanxuan Wang, i wsp.
Wydane: (2022-09-01)

Dynamics of CXC group chemokine platelet factor 4 (PF4) plasma levels in non-small cell lung cancer (NSCLC)
od: Spaks Artjoms, i wsp.
Wydane: (2012-11-01)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
od: Hong‐Shuai Li, i wsp.
Wydane: (2022-02-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
od: Hui Zhang, i wsp.
Wydane: (2022-04-01)

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
od: Kamrine E. Poels, i wsp.
Wydane: (2021-06-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
od: Leydis Luna Torres, i wsp.
Wydane: (2021-10-01)

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors
od: Raelene Endersby, i wsp.
Wydane: (2018-05-01)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
od: Masahiro Iwasaku, i wsp.
Wydane: (2023-07-01)

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
od: Kamrine E. Poels, i wsp.
Wydane: (2022-09-01)

Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib
od: Ana Ruiz-Garcia, i wsp.
Wydane: (2020-04-01)

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
od: Manal A. Alossaimi, i wsp.
Wydane: (2023-03-01)

A New Series of Indeno[1,2-<i>c</i>]pyrazoles as EGFR TK Inhibitors for NSCLC Therapy
od: Ahmet Özdemir, i wsp.
Wydane: (2022-01-01)

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
od: Hong-Shuai Li, i wsp.
Wydane: (2022-06-01)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
od: Weise AM, i wsp.
Wydane: (2014-08-01)

Downregulation of MerTK in circulating T cells of patients with non-proliferative diabetic retinopathy
od: Shimiao Bu, i wsp.
Wydane: (2025-01-01)

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma
od: Ailing Liu, i wsp.
Wydane: (2025-02-01)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
od: Yibin Li, i wsp.
Wydane: (2022-08-01)

TK Solver Plus : introduction to TK Solver Plus /
Wydane: (1989)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
od: Wen-Chien Cheng, i wsp.
Wydane: (2024-02-01)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
od: Hisashi Tanaka, i wsp.
Wydane: (2022-05-01)

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
od: Nagasaka M, i wsp.
Wydane: (2019-09-01)

Misrepresentation, Mistake and Non-Disclosure, 3rd edn
od: Cartwright, J
Wydane: (2012)

Snapshots of a Non-Canonical RdRP in Action
od: Diego S. Ferrero, i wsp.
Wydane: (2021-06-01)

Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
od: Majid Momeny, i wsp.
Wydane: (2017-06-01)

Roark & Young on TK : TK menuing system & RY Tutor
Wydane: (1989)

Diagnostic bronchoscopy: a window of opportunity for timely biomarker driven therapy in non-small cell lung cancer (NSCLC)
od: Medley, L, i wsp.
Wydane: (2009)

Up-regulation of sonic hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells.
od: Ma'in Y Maitah, i wsp.
Wydane: (2011-01-01)